Testosterone potentiated32P therapy in prostatic carcinoma

Twelve patients with metastatic prostatic carcinoma and intractable bone pain were treated with testosterone potentiated 32P therapy. One patient expired prior to the completion of therapy; in the remaining 11 patients there was marked relief of pain allowing the discontinuance of narcotics for an average period of 6.3 months. In 9 of the 11 patients radiographic improvement of osseous metastases was demonstrated. The authors conclude that testosterone potentiated 32P therapy is a valuable adjunct in the palliative therapy of metastatic osseous prostatic cancer.